| Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. | prostate, |
| Based on these results we have formulated a hypothesis about the different types of endometrial hyperplasia morphogenesis and its possible transfer to cervical cancer associated with features of tumor suppressor gene PTEN. | cervical,endometrial, |
| this study was focused on aberrations of the tumor suppressor genes TP53 and PTEN in cancer stromal fibroblasts of breast cancer. | breast, |
| miR-23b-3p is an oncogenic miRNA and inhibits PTEN tumor suppressor gene in renal cell carcinoma. | kidney, |
| Reactivation of PTEN tumor suppressor pathway leads to a 50% reduction in colorectal cancer metastasis without affecting primary tumor formation. | colorectal, |
| PTEN functions as a melanoma tumor suppressor in part by regulating the host immune response. | skin, |
| The data in this study suggest that 2ME2 may be more efficacious in patients whose GBM tumors express a wild type PTEN tumor suppressor protein. | GBM, |
| Data indicate that NVP-BEZ235-induced androgen receptor (AR) suppression resulted in decreased expression of both tumor suppressor proteins PTEN and KLLN in AR+/ER+ breast cancer cells. | breast, |
| show how CBP and PTEN interact to mediate tumor suppression in the prostate, establishing a central role for histone modification in the etiology of prostate cancer | prostate, |
| miR-21 is overexpressed in gastric cancer and its aberrant expression may have important role in gastric cancer growth and dissemination by modulating the expression of the tumor suppressors PTEN and PDCD4 | gastric, |
| the PTEN tumor suppressor pathway has a role in carcinoma in situ of the bladder | bladder, |
| Alteration of EBV encoded miR-BART1 expression results in an increase in migration and invasion of nasopharyngeal carcinoma in vitro and causes metastasis in vivo. EBV-miR-BART1 directly targets the cellular tumour suppressor PTEN. | nasopharyngeal,laryngeal, |
| Hypermethylation status of PTEN tumor suppressor gene is associated with breast cancer. | breast, |
| miR-21 can confer drug resistance to 5-FU in pancreatic cancer cells by regulating the expression of tumor suppressor genes, as the target genes of miR-21, PTEN and PDCD4 can rescue 5-FU sensitivity and the phenotypic characteristics disrupted by miR-21. | pancreatic, |
| PTEN, a well-defined tumor suppressor was identified to be a target gene of miR-495. Rescue experiments showed that enforced expression of PTEN impaired miR-495-mediated bladder cancer proliferation and invasion. | bladder, |
| the impact of autophagy loss in a different model of PDAC driven by oncogenic KRAS (G12D) combined with deficiency of the tumor suppressor, Phosphatase and Tensin Homolog (PTEN)-a factor lost in pancreatic ductal adenocarcinoma, was examined. | pancreatic, |
| we demonstrate that PKCepsilon cooperates with the loss of the tumor suppressor Pten for the development of prostate cancer in a mouse model. Mechanistic analysis revealed that PKCe overexpression and Pten loss individually and synergistically upregulate the production of the chemokine CXCL13, which involves the transcriptional activation of the CXCL13 gene | prostate, |
| E2 is able to inhibit ERbeta expression and suggest that the tumor suppressor PTEN might be one of the signaling proteins by which E2, through ERbeta, acts to modulate pituitary cell proliferation. | pituitary, |
| Ectopic PTEN overexpression in bladder cancer cells blocked the Akt signal pathway which attenuated cell growth via upregualtion of BTG2 gene expression, while reverse effect was found in PTEN-knockdown cells. PTEN activity inhibitor treatment decreased BTG2 expression in Highly differentiated bladder cancer cells. Results suggested that BTG2 functioned as a bladder cancer tumor suppressor gene and was induced by PTEN. | bladder, |
| Here, we characterized the immune-cell composition of prostate cancers driven by the loss of the critical tumor suppressor gene Pten, either alone or in combination with the loss of Trp53, Zbtb7a or Pml. | prostate, |